ArticleImmunity, inflammation and disease2025
Serum SERPINB3/4 in Moderate-to-Severe Prurigo Nodularis: A Potential Biomarker for Disease Severity and Eosinophil-Related Parameters.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum SERPINB3/4 in Moderate-to-Severe Prurigo Nodularis: A Potential Biomarker for Disease Severity and Eosinophil-Related Parameters.Immunity, inflammation and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe available evidence increasingly indicates that SERPINB3/4 plays a pivotal role in the progression of inflammatory diseases and may serve as a valuable biomarker for atopic dermatitis and psoriasis. However, the expression of SERPINB3/4 in the serum of patients with moderate-to-severe prurigo nodularis (PN) remains poorly understood.
objectiveTo find a promising biomarker for monitoring the severity and activity of moderate-to-severe PN patients.
methodsA total of 41 patients with moderate-to-severe PN and 20 healthy subjects were included in the study. Enzyme-linked immunosorbent assay (ELISA) was performed to determine serum SERPINB3/4 expression. Cutaneous SERPINB3/4 expression was evaluated by immunohistochemistry (IHC). Serum SERPINB3/4 levels were correlated with PN disease severity and activity scores, hematological parameters, and systemic inflammatory markers.
resultsSERPINB3/4 expression was found to be significantly increased in the serum and lesions of PN in comparison to healthy subjects. In patients with PN, the expression of serum SERPINB3/4 was significantly elevated in subjects with higher investigator global assessment (IGA) scores, while exhibiting a notable decline in patients with higher pruritus numeric rating scale (P-NRS) scores. Positive correlations were observed between serum SERPINB3/4 levels and peripheral eosinophil count, eosinophil ratio, and eosinophil-to-lymphocyte ratio (ELR) in patients with PN.
conclusionSERPINB3/4 expression was increased in PN sera and lesions. Serum SERPINB3/4 expression was positively correlated with PN severity and peripheral eosinophil-related parameters, suggesting its potential as a promising biomarker for PN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.